Developing Digital in the Oilfield

Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) discussed screen design, target bias, and hit-prioritization strategies to identify those entities with the greatest opportunity to be developed into the next new antibiotic.

Viscoelasticity is a term used to describe materials that exhibit both viscous flow and elastic spring back when a force is applied to them.

Greater complexity, disjointed systems or too costly market solutions are the enemies of chemical manufacturers & distributors – occurring when ERP, CRM, & supply chain processes are allowed to operate in silos. Thankfully, today’s business management solutions have been evolving to meet the industry’s complex demands.

The process of drug discovery and development is a path that enlists the expertise of many while in pursuit of the one novel entity that rises above a host of potential candidates. For peptides this can be a daunting task given molecule complexity, physiochemical properties, receptor selectivity and scale-up of material. This presentation will discuss the discovery of our Glucagon agonist and how to use innovative technologies, focused SAR, and effective integration of a unique multidisciplinary team in the drug discovery process.